Congenital Adrenal Hyperplasia (CAH)

Definition

Pathophysiology

1. Cholesterol side-chain cleavage enzyme (P450scc / StAR)
2. 3β-hydroxysteroid dehydrogenase (3β-HSD)
3. 17α-hydroxylase (CYP17A1)
4. 21-hydroxylase (CYP21A2) - most common
5. 11β-hydroxylase (CYP11B1)

Enzyme Deficiencies: Summary

21-Hydroxylase Deficiency (CYP21A2 Deficiency)

Genetics

• Autosomal recessive; gene located at chromosome 6p21.3 within the HLA complex
• Adjacent to the active CYP21A2 gene lies the highly homologous (98%) pseudogene CYP21PA1; gene conversion during meiosis can inactivate CYP21A2
• Over 200 different mutations reported; ~10 mutations account for 90-95% of all alleles
• Incidence: 1 in 5,000 to 1 in 15,000 (US and Europe); highest in Yupik Alaskan Eskimos (1 in 490)
• Campbell-Walsh Urology, p. 1291

Clinical Forms

• Residual enzyme activity: 0-1%
• Both glucocorticoid AND mineralocorticoid deficiency
• Females: ambiguous genitalia at birth
• Males: normal-appearing genitalia at birth; present with adrenal crisis (hyponatremia, hyperkalemia, vomiting, shock) at 1-3 weeks of life - easily missed
• ~75% of classic CAH cases

• Residual enzyme activity: 2-20%
• Glucocorticoid deficiency + androgen excess; mineralocorticoid synthesis partially preserved
• Females: virilized genitalia at birth
• Males: early virilization at 2-4 years (pubic hair, penile enlargement, advanced bone age)
• ~25% of classic CAH cases

• Residual enzyme activity: 20-50%
• No glucocorticoid or mineralocorticoid deficiency
• Presents in adolescence/adulthood: hirsutism, acne, menstrual irregularities, infertility, PCOS-like picture
• Most common form overall; often underdiagnosed

Clinical Features

Females (46,XX) with Classic CAH

• In utero androgen exposure begins at ~10 weeks gestation, affecting external genitalia development
• Clitoromegaly and labial fusion are invariably present to some degree
• Vagina and urethra open into a common urogenital sinus
• Internal (Mullerian) structures (uterus, fallopian tubes, ovaries) are normal
• Severity graded by the Prader classification (I-V), ranging from mild clitoromegaly to fully masculinized appearance
• Campbell-Walsh Urology, p. 1291

Males (46,XY) with Classic CAH

• External genitalia appear normal at birth
• Salt-wasting crisis typically presents at 7-14 days with vomiting, dehydration, poor feeding, and cardiovascular collapse
• Simple virilizers: early pubic hair, penile growth, tall childhood stature (but premature epiphyseal fusion leads to short adult stature)
• Testicular adrenal rest tumors (TARTs) can develop and cause gonadal damage

Metabolic/Long-term Consequences

• Adrenal crisis (life-threatening) in inadequately treated or stressed patients
• Short stature (premature bone age advancement)
• Subfertility in both sexes (androgen/progesterone effects on gonadal axis)
• Obesity, hypertension, insulin resistance with chronic glucocorticoid over-treatment
• Psychosocial issues and gender identity questions in virilized 46,XX females

Diagnosis

Newborn Screening

• Newborn screening for CAH is performed in all 50 US states and >40 countries using 17-hydroxyprogesterone (17-OHP) from dried blood spot
• Has dramatically improved time to diagnosis, especially for males with salt-wasting form
• False positives common in premature/low-birth-weight infants; weight- and gestational-age-adjusted reference ranges used

Key Laboratory Findings

• "A very high concentration of 17-hydroxyprogesterone in a randomly timed blood sample is diagnostic of classic 21-hydroxylase deficiency. Salt-wasting patients have higher 17-OHP than non-salt losers." - Quick Compendium of Clinical Pathology, p. 46
• ACTH stimulation test for borderline/non-classic cases
• Genetic analysis of CYP21A2 (not always needed to confirm diagnosis but useful for counseling)

Management

Glucocorticoid Replacement

• Hydrocortisone is the drug of choice in children (10-15 mg/m²/day in 2-3 divided doses)
• Goal: suppress morning 17-OHP to 300-900 ng/dL (Berek & Novak); normalization indicates over-treatment
• Dexamethasone or prednisone used in adults; dexamethasone avoided in pregnancy (replaced with hydrocortisone)
• Stress dosing (2-3x usual dose) required during fever, illness, surgery to prevent adrenal crisis

Mineralocorticoid Replacement

• Fludrocortisone required in salt-wasting form (and often in simple virilizing form too)
• Goal: suppress plasma renin activity to <5 ng/mL/hour
• Sodium supplementation needed in infants (1-2 g NaCl/day)

Surgical Management (46,XX Females)

• Girls with ambiguous genitalia may require clitoral recession and/or vaginoplasty
• Timing is debated; child must be of appropriate size for optimal surgical outcomes
• Early surgery can address psychosocial impact of ambiguous genitalia
• Berek & Novak's Gynecology, p. 362

Monitoring

• 17-OHP, androstenedione, testosterone levels
• Bone age assessments (X-ray left hand/wrist)
• Growth charts and final height prediction
• Plasma renin activity (mineralocorticoid adequacy)

Prenatal Diagnosis and Treatment

• At-risk pregnancies (both parents carriers or one parent affected): prenatal diagnosis via CVS or amniocentesis
• Elevated 17-OHP or 21-deoxycortisol in amniotic fluid, or direct CYP21A2 genetic analysis
• Dexamethasone administered to the mother crosses the placenta and can reduce/prevent virilization of an affected female fetus
• Treatment must be started early (before 6-7 weeks gestation) to be effective
• Maternal risks include hypercortisolism; fetal neurodevelopmental and physical effects remain uncertain
• Not all affected female fetuses benefit (treatment is 1 in 8 chance of preventing virilization in a given pregnancy)
• Berek & Novak's Gynecology, p. 362; Creasy & Resnik's Maternal-Fetal Medicine

11β-Hydroxylase Deficiency

• Second most common form (~5% of CAH)
• Block causes accumulation of 11-deoxycortisol and deoxycorticosterone (DOC)
• DOC has mineralocorticoid activity → hypertension (contrasting with salt-wasting in 21-OH deficiency)
• Androgen excess → virilization of females
• Diagnosis: ACTH stimulation test shows elevation of DOC and 11-deoxycortisol with suppressed plasma renin activity
• Treatment: glucocorticoids (suppress ACTH and thereby DOC)
• Brenner and Rector's The Kidney, p. 1818

Emerging Therapies

• Modified-release hydrocortisone (Plenadren, Chronocort) - mimics physiological cortisol rhythm better
• Hydrocortisone pump - continuous subcutaneous infusion
• CRF1 receptor antagonists - suppress excessive CRH signaling
• Anti-ACTH monoclonal antibodies (preclinical)
• Androgen receptor antagonists - block androgen effects at target tissues
• Gene therapy / cell-based therapies (preclinical)

Genetics and Counseling

• All forms of CAH are autosomal recessive
• Parents of an affected child each carry at least one affected haplotype → 25% risk in each subsequent pregnancy, 50% carrier risk
• A woman with CAH and an unaffected partner: 100% of offspring are carriers
• A woman with CAH and a carrier partner: 50% affected, 50% carriers
• Creasy & Resnik's Maternal-Fetal Medicine

1. 21-Hydroxylase deficiency = 95% of all CAH
2. Salt-wasting (classic severe): life-threatening crisis in neonates; female virilization
3. 17-OHP is the diagnostic cornerstone; newborn screening available
4. Treatment = glucocorticoid + mineralocorticoid replacement + stress dosing
5. 11β-Hydroxylase deficiency: HTN + virilization (not salt-wasting)
6. Non-classic CAH: presents in adolescence/adulthood with hyperandrogenism, often mistaken for PCOS

Congenital Adrenal Hyperplasia (CAH)

Definition

Pathophysiology

1. Cholesterol side-chain cleavage enzyme (P450scc / StAR)
2. 3β-hydroxysteroid dehydrogenase (3β-HSD)
3. 17α-hydroxylase (CYP17A1)
4. 21-hydroxylase (CYP21A2) - most common
5. 11β-hydroxylase (CYP11B1)

Enzyme Deficiencies: Summary

21-Hydroxylase Deficiency (CYP21A2 Deficiency)

Genetics

• Autosomal recessive; gene located at chromosome 6p21.3 within the HLA complex
• Adjacent to the active CYP21A2 gene lies the highly homologous (98%) pseudogene CYP21PA1; gene conversion during meiosis can inactivate CYP21A2
• Over 200 different mutations reported; ~10 mutations account for 90-95% of all alleles
• Incidence: 1 in 5,000 to 1 in 15,000 (US and Europe); highest in Yupik Alaskan Eskimos (1 in 490)

Clinical Forms

• Residual enzyme activity: 0-1%
• Both glucocorticoid AND mineralocorticoid deficiency
• Females: ambiguous genitalia at birth
• Males: normal-appearing genitalia at birth; present with adrenal crisis (hyponatremia, hyperkalemia, vomiting, shock) at 1-3 weeks of life
• ~75% of classic CAH cases

• Residual enzyme activity: 2-20%
• Glucocorticoid deficiency + androgen excess; mineralocorticoid synthesis partially preserved
• Females: virilized genitalia at birth
• Males: early virilization at 2-4 years (pubic hair, penile enlargement, advanced bone age)
• ~25% of classic CAH cases

• Residual enzyme activity: 20-50%
• No glucocorticoid or mineralocorticoid deficiency
• Presents in adolescence/adulthood: hirsutism, acne, menstrual irregularities, infertility, PCOS-like picture
• Most common form overall; often underdiagnosed

Clinical Features

Females (46,XX) with Classic CAH

• In utero androgen exposure begins at ~10 weeks gestation
• Clitoromegaly and labial fusion invariably present to some degree
• Vagina and urethra open into a common urogenital sinus
• Internal Mullerian structures (uterus, fallopian tubes, ovaries) are normal
• Severity graded by the Prader classification (I-V)

Males (46,XY) with Classic CAH

• External genitalia appear normal at birth
• Salt-wasting crisis typically at 7-14 days: vomiting, dehydration, cardiovascular collapse
• Simple virilizers: early pubic hair, penile growth, tall childhood stature but short adult stature (premature epiphyseal fusion)
• Testicular adrenal rest tumors (TARTs) can develop and cause gonadal damage

Long-term Consequences

• Adrenal crisis (life-threatening) with illness/stress
• Short stature from premature bone age advancement
• Subfertility in both sexes
• Obesity, hypertension, insulin resistance with glucocorticoid over-treatment
• Psychosocial issues and gender identity concerns in virilized 46,XX females

Diagnosis

Newborn Screening

• Performed in all 50 US states and >40 countries via dried blood spot 17-OHP
• False positives common in premature/low-birth-weight infants; weight- and gestational-age-adjusted reference ranges used

Key Laboratory Findings

• A very high basal 17-OHP is diagnostic of classic 21-OH deficiency; ACTH stimulation test used for borderline/non-classic cases
• Genetic analysis of CYP21A2 for counseling and equivocal cases

Management

Glucocorticoid Replacement

• Hydrocortisone is the drug of choice in children (10-15 mg/m²/day in 2-3 divided doses)
• Goal: suppress morning 17-OHP to 300-900 ng/dL; normalization = over-treatment
• Prednisone or dexamethasone used in adults
• Dexamethasone avoided in pregnancy (replaced with hydrocortisone to avoid fetal exposure)
• Stress dosing (2-3x usual dose) during fever, illness, or surgery

Mineralocorticoid Replacement

• Fludrocortisone required in salt-wasting form (and generally in simple virilizing form)
• Goal: suppress plasma renin activity to <5 ng/mL/hour
• Sodium supplementation in infants (1-2 g NaCl/day)

Surgical Management (46,XX Females)

• Clitoral recession and/or vaginoplasty for ambiguous genitalia
• Timing debated; child must be of appropriate size for optimal outcomes

Monitoring

• 17-OHP, androstenedione, testosterone
• Bone age (X-ray left hand/wrist)
• Growth charts and final height prediction
• Plasma renin activity

Prenatal Diagnosis and Treatment

• Diagnosis via CVS or amniocentesis: elevated amniotic 17-OHP or 21-deoxycortisol, or direct CYP21A2 genotyping
• Dexamethasone to mother (crosses placenta) can reduce/prevent virilization of affected female fetus
• Must be started before 6-7 weeks gestation to be effective; only 1 in 8 pregnancies at risk actually benefits
• Maternal risks: hypercortisolism; fetal neurodevelopmental effects remain uncertain

11β-Hydroxylase Deficiency

• Second most common (~5% of CAH)
• Accumulation of deoxycorticosterone (DOC) - a mineralocorticoid - causes hypertension (contrasts with salt-wasting in 21-OH deficiency)
• Androgen excess → virilization
• Diagnosis: ACTH stimulation shows elevated DOC and 11-deoxycortisol with suppressed plasma renin activity
• Treatment: glucocorticoids (suppress ACTH and thereby DOC)

Genetics and Counseling

• All forms autosomal recessive
• Parents of an affected child: 25% risk in each subsequent pregnancy, 50% carrier risk
• Woman with CAH + unaffected partner: 100% of offspring are carriers
• Woman with CAH + carrier partner: 50% affected, 50% carriers

Emerging Therapies

• Modified-release hydrocortisone (Plenadren, Chronocort) - mimics physiological cortisol circadian rhythm
• Hydrocortisone pump - continuous subcutaneous infusion
• CRF1 receptor antagonists - suppress excessive hypothalamic CRH signaling
• Anti-ACTH monoclonal antibodies (preclinical)
• Androgen receptor antagonists - block androgen effects at target tissues
• Gene therapy / cell-based therapies (preclinical)

References

1. Goldman L, Schafer AI, eds. Goldman-Cecil Medicine, 27th ed. Philadelphia: Elsevier; 2024. Chapter 214, pp. 2515-2516. [Congenital Adrenal Hyperplasia]
2. Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, eds. Campbell Walsh Wein Urology, 12th ed. Philadelphia: Elsevier; 2021. Chapter 48, pp. 1290-1294. [Congenital Adrenal Hyperplasia - Adrenogenital Syndrome]
3. Berek JS, ed. Berek & Novak's Gynecology, 16th ed. Philadelphia: Wolters Kluwer; 2020. Chapter 8, pp. 361-362. [Treatment of Congenital Adrenal Hyperplasia; 21-Hydroxylase Deficiency]
4. Creasy RK, Resnik R, Iams JD, et al., eds. Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice, 8th ed. Philadelphia: Elsevier; 2022. Chapter 62, pp. 3327-3344. [Congenital Adrenal Hyperplasia in Pregnancy]
5. McPherson RA, Pincus MR, eds. Quick Compendium of Clinical Pathology, 5th ed. Chicago: ASCP Press. Table 1.34, p. 46. [Congenital Adrenal Hyperplasia - Diagnosis and Treatment]
6. Brenner BM, ed. Brenner and Rector's The Kidney, 11th ed. Philadelphia: Elsevier; 2020. Chapter 26, p. 1818. [11β-Hydroxylase Deficiency]
7. El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet. 2017;390(10108):2194-2210. [PMID: 28576284]
8. Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, et al. Congenital adrenal hyperplasia - current insights in pathophysiology, diagnostics and management. Endocr Rev. 2022;43:91-159.
9. Hannah-Shmouni F, Chen W, Merke DP. Genetics of congenital adrenal hyperplasia. Endocrinol Metab Clin North Am. 2017;46(2):435-458.
10. Witchel SF. Congenital adrenal hyperplasia. J Pediatr Adolesc Gynecol. 2017;30(5):520-534.

Adrenal Crisis (Acute Adrenal Insufficiency / Addisonian Crisis)

Definition

Etiology and Precipitating Causes

Underlying Conditions that Set the Stage

Common Precipitating Triggers (in patients with pre-existing adrenal insufficiency)

• Infections (most common) - especially GI infections causing vomiting/diarrhea with inability to absorb oral steroids
• Fever
• Surgery or trauma
• Extreme physical exertion
• Burns
• Acute severe injury
• Cessation or missed doses of glucocorticoid replacement

Pathophysiology

1. Mineralocorticoid (aldosterone) deficiency - inability to maintain sodium and intravascular volume; sodium wasting, hypovolemia, and vascular collapse
2. Glucocorticoid (cortisol) deficiency - diminished cardiovascular responsiveness to catecholamines; hypotension refractory to vasopressors

Clinical Features

Symptoms

• Severe hypotension - often refractory to vasopressors (hallmark)
• Nausea, vomiting, diarrhea - can mimic acute abdomen
• Severe abdominal pain - may lead to misdiagnosis as surgical emergency
• Fever (even without identifiable infection)
• Profound weakness, lethargy, fatigue
• Confusion, disorientation - altered mental status
• Salt craving, syncope
• Hypoglycemia - especially in children

Signs Distinguishing Primary vs. Secondary Adrenal Crisis

• Tintinalli's Emergency Medicine, p. 1500

Diagnostic Approach

Critical rule: Do NOT delay treatment while awaiting results. If adrenal crisis is clinically suspected, treat immediately. - Rosen's Emergency Medicine

Immediate Bedside Tests

• Bedside glucose - identify hypoglycemia urgently
• Serum electrolytes - Na⁺ (↓), K⁺ (↑ in primary), Cl⁻
• Full blood count - eosinophilia may be present
• Serum cortisol - if available; a level >18 µg/dL generally excludes adrenal insufficiency
• ECG - for hyperkalemia-related changes
• ABG - mild metabolic acidosis from tissue hypoxia

Confirmatory Tests (after stabilization)

• ACTH stimulation test (Synacthen/Cosyntropin test):
  • Baseline cortisol drawn
  • 250 µg cosyntropin (synthetic ACTH) given IV
  • Serum cortisol measured at 30-60 minutes
  • Stimulated cortisol <18 µg/dL = adrenal insufficiency
  • A significant rise post-stimulation suggests secondary insufficiency
• Morning ACTH level (after diagnosis confirmed): differentiates primary (high ACTH) from secondary (low ACTH)
• Imaging: CT abdomen (adrenal hemorrhage/infarction); CT/MRI head (pituitary/hypothalamic lesion)

If ACTH stimulation test is planned and steroids must be given urgently, use dexamethasone - it does not cross-react with cortisol assays. Add fludrocortisone alongside it, as dexamethasone has no mineralocorticoid activity. - Tintinalli's Emergency Medicine

Emergency Management

Step 1 - Secure IV Access and Draw Blood First

• Collect cortisol, ACTH, electrolytes, glucose - but do NOT delay treatment

Step 2 - IV Fluids (Immediate Priority)

• Normal saline (0.9% NaCl) - 2-3 litres in the first 6 hours
• If hypoglycemic: use dextrose-containing saline (D5/NS) - begin immediately
• Fluid resuscitation precedes vasopressors

Step 3 - Glucocorticoid Replacement (Emergency Dose)

• Tintinalli's Emergency Medicine, Table 230-4; Bailey & Love's Surgery

Step 4 - Mineralocorticoid Replacement

• Not an early priority in acute crisis - high-dose hydrocortisone has sufficient mineralocorticoid activity, and saline infusion rapidly corrects electrolyte imbalance
• Fludrocortisone is started once oral intake resumes and hydrocortisone dose is tapered below 50 mg/day
• Sabiston Textbook of Surgery

Step 5 - Vasopressors (Last Resort)

• Add vasopressors (norepinephrine, dopamine, or phenylephrine) only after steroid therapy in patients unresponsive to aggressive fluid resuscitation
• Catecholamine resistance is caused by cortisol deficiency and reverses with glucocorticoid replacement

Step 6 - Supportive Care

• Maintain airway, breathing, circulation
• Correct electrolyte imbalances (sodium, potassium, calcium)
• Treat the precipitating cause (antibiotics for infection, etc.)
• Consider glucose, thiamine, naloxone for altered mental status

Dose Tapering

• Taper hydrocortisone by 50% per day once the patient is clinically stable
• Switch to oral maintenance once tolerated
• Goldman-Cecil Medicine

Perioperative Steroid Coverage

Chronic Maintenance Therapy (Post-Crisis)

• During illness/fever: double the usual hydrocortisone dose ("sick day rules")
• If vomiting/severe diarrhea/collapse: IM hydrocortisone 50-100 mg before transport to hospital
• Assess adequacy by: clinical symptoms, plasma ACTH (should remain 100-200 pg/mL), plasma renin (normalizes with adequate fludrocortisone)
• Goldman-Cecil Medicine

Patient Education and Prevention

• Never stopping steroids abruptly
• Wearing a medical alert bracelet/necklace identifying steroid dependence
• Sick day rules - doubling dose with illness, when to give IM injection
• Carrying an emergency hydrocortisone injection kit at all times
• Informing all healthcare providers (dentists, surgeons) about their steroid dependence
• Goldman-Cecil Medicine

Special Situations

Waterhouse-Friderichsen Syndrome

• Bilateral adrenal hemorrhage caused by fulminant septicemia (classically meningococcemia, also pneumococcal)
• Produces sudden, complete loss of adrenal function
• Presents with septic shock + adrenal crisis simultaneously
• Requires immediate IV hydrocortisone + aggressive sepsis management

CAH Neonatal Adrenal Crisis

• Salt-wasting 21-OH deficiency: presents at 7-14 days of life with vomiting, poor feeding, hyponatremia, hyperkalemia, cardiovascular collapse
• Males particularly at risk of delayed diagnosis (normal-appearing genitalia)
• Treat with IV hydrocortisone + saline + fludrocortisone once stabilized

Thyroid Hormone Replacement Pitfall

• Starting levothyroxine in a patient with unrecognized central adrenal insufficiency can precipitate adrenal crisis (increased cortisol metabolism)
• Always exclude adrenal insufficiency before starting thyroid replacement in central hypothyroidism

Prognosis

• Adrenal crisis is rapidly fatal without treatment
• With prompt recognition and treatment, prognosis is good
• Crisis recurrence rate: 8.3 per 100 patient-years even in educated patients
• ICU admission indicated for severe cases; mortality is high if untreated
• Rosen's Emergency Medicine; Bailey & Love's Surgery

References

1. Tintinalli JE, et al., eds. Tintinalli's Emergency Medicine: A Comprehensive Study Guide, 9th ed. New York: McGraw-Hill; 2020. Chapter 230, pp. 1499-1503. [Adrenal Crisis - Clinical Features, Lab Studies, Treatment Table 230-4]
2. Townsend CM, et al., eds. Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice, 21st ed. Philadelphia: Elsevier; 2022. Chapter 75, pp. 1563-1564. [Adrenal Crisis - Pathogenesis, Diagnosis, Perioperative Steroid Coverage]
3. Norman Williams, et al., eds. Bailey and Love's Short Practice of Surgery, 28th ed. Boca Raton: CRC Press; 2022. Chapter 52, pp. 8352-8388. [Acute Adrenal Insufficiency - Diagnosis and Treatment]
4. Goldman L, Schafer AI, eds. Goldman-Cecil Medicine, 27th ed. Philadelphia: Elsevier; 2024. Chapter 214, pp. 2458. [Patient Education, Stress Dosing, Prognosis of Adrenal Crisis]
5. Walls RM, et al., eds. Rosen's Emergency Medicine: Concepts and Clinical Practice, 9th ed. Philadelphia: Elsevier; 2018. Chapter 117, Box 117.11. [Treatment of Hypoadrenalism - Adrenal Crisis and Maintenance]
6. Bornstein SR, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-389.
7. Rushworth RL, Torpy DJ, Falhammar H. Adrenal crises: perspectives and research directions. Endocrine. 2017;55(2):336-345.

• Prioritize pediatric textbooks - Nelson Textbook of Pediatrics, Harriet Lane Handbook, Nelson Essentials, Forfar & Arneil, etc.
• Search pediatric-focused PubMed sources - journals like Pediatrics, Journal of Pediatrics, Archives of Disease in Childhood, pediatric-specific guidelines (AAP, ESPGHAN, ISPAD, etc.)
• Tailor clinical content to pediatric age groups - neonates, infants, children, adolescents - with age-appropriate dosing, presentations, and management
• Reference pediatric normal values where relevant (growth, vitals, lab ranges by age)

Cerebral Palsy (CP)

Definition

1. A disorder of movement and posture (weakness, spasticity, dystonia, ataxia, or choreoathetosis) with onset before age 1-2 years
2. Reliable evidence of disturbance in the fetal or infant brain
3. No evidence of progression over time
4. Significant functional limitation in desired activities
5. Reasonable expectation the disorder will persist throughout life

Although called "static encephalopathy," the clinical expression is dynamic - it evolves with growth and aging. CP should NOT be diagnosed if the disorder is very mild, may disappear, begins after infancy, is progressive, or is due to a spinal/neuromuscular etiology.

Epidemiology

• Most common neuromotor disorder in childhood
• Incidence: ~2 per 1,000 live births at term
• In very premature infants: 40-60 per 1,000 (up to 30x higher risk)
• Congenital CP (injury before/during birth): 85-90% of all cases
• Acquired CP (injury after 1 month of life): 10-15%
• Bradley & Daroff's Neurology, p. 2878

Etiology

By Timing of Insult

Prematurity and PVL are the most common identifiable risk factors overall. Specific causes like HIE can be identified only in a minority of cases.

Classification

By Motor Type (Physiologic)

Hypotonia may be an early phase before spasticity develops in many children.

By Topographic Distribution (Spastic CP)

Clinical Features and Associated Conditions

Motor Features

• Positive features: ↑ deep tendon reflexes, clonus, spasticity, extensor plantar response (Babinski sign)
• Negative features: muscle weakness, loss of dexterity

• Spastic diplegia: scissor gait (hip adduction/internal rotation, knees close together, in-toeing)
• Spastic hemiplegia: circumduction gait, equinus foot on affected side, arm held in flexion

Associated (Non-Motor) Conditions

Gross Motor Function Classification System (GMFCS)

GMFCS IV-V patients have nearly 50% risk of developing spinal deformity. - Campbell's Operative Orthopaedics

Neuroimaging

• Brain MRI is the investigation of choice (preferred over CT/ultrasound)
• Imaging correlates with clinical type and etiology:
  • PVL (periventricular white matter loss) → spastic diplegia (premature infants)
  • Basal ganglia/thalamus involvement → dyskinetic CP (~70% of dyskinetic CP)
  • Hemispheric lesion / perinatal stroke → spastic hemiplegia
  • Kernicterus → preferential involvement of the globus pallidus
• Up to 13% of dyskinetic CP may have a normal MRI - raise suspicion for underlying genetic/metabolic disorder
• Bradley & Daroff's Neurology, p. 2879

When to Suspect Genetic Cause (Not Acquired CP)

• Normal MRI with no identifiable risk factors
• Progressive or atypical course
• Strong family history
• Associated dysmorphic features or multi-organ involvement
• Genetic testing (chromosomal microarray, exome sequencing) increasingly recommended

Diagnosis

• History of risk factors (prematurity, HIE, meningitis, etc.)
• Failure to achieve motor milestones (delayed gross/fine motor)
• Abnormal neurological examination (tone, reflexes, posture)
• Non-progressive course
• Supportive neuroimaging

• Persistent fisting beyond 3-4 months
• Asymmetric hand use before 18 months (hemiplegic)
• Absent head control by 4 months
• Absent sitting by 9-10 months
• Hypotonia or unusual stiffness
• Scissoring when held vertical

Management

1. Spasticity Management

A. Physical and Occupational Therapy

• Foundation of all CP management
• Stretching, strengthening, constraint-induced movement therapy (hemiplegia)
• Orthoses (AFOs - ankle-foot orthoses) to maintain alignment and prevent contractures

B. Botulinum Toxin A (BTX-A)

• First-line focal spasticity treatment in children
• Injected into spastic muscles; reduces spasticity for 3-6 months
• Common targets: gastrocnemius (equinus), hip adductors (scissoring), hamstrings, upper limb flexors
• Best used in conjunction with physiotherapy and casting
• Repeat injections possible; greatest benefit in GMFCS I-III

C. Oral Medications

D. Intrathecal Baclofen (ITB) Pump

• Continuous baclofen delivered directly into CSF via implanted pump
• Indicated for severe generalized spasticity not controlled by oral agents (GMFCS III-V)
• Avoids systemic side effects; highly effective
• Requires surgical implantation and ongoing pump refills

E. Selective Dorsal Rhizotomy (SDR)

• Neurosurgical procedure: selective division of posterior (sensory) nerve rootlets at L1-S1 level
• Permanently reduces spasticity in lower limbs
• Best candidates: spastic diplegic CP, GMFCS II-III, good selective motor control, age 4-8 years
• Requires intensive post-operative physiotherapy (1-2 years)
• Not effective for dystonia

2. Orthopaedic Management

Common Surgical Procedures

• Single-Event Multilevel Surgery (SEMLS) - preferred approach: multiple procedures performed in one operation to minimize repeated hospitalizations and rehabilitation
• Campbell's Operative Orthopaedics, p. 7602

Hip Surveillance

• Hip displacement/dislocation is a major complication - especially in GMFCS IV-V
• Surveillance program: regular hip radiographs based on GMFCS level from early childhood until skeletal maturity
• Early intervention (soft tissue releases) before dislocation occurs is preferred

Scoliosis

• Most common in quadriplegic CP, GMFCS IV-V (~50% risk)
• Bracing: temporizing in progressive curves; rarely effective long-term
• Surgery indicated for curves >50 degrees in skeletally immature children
• Fusion to pelvis often required to address pelvic obliquity
• Complication rate up to 81% (infection 15-19%); pulmonary complications common

3. Associated Condition Management

4. Goal-Setting and Rehabilitation

• Body structure/function: reduce spasticity, prevent contractures
• Activity: maximize functional independence (walking, self-care, communication)
• Participation: school inclusion, social participation, quality of life

Prognosis

• Life expectancy correlates with mobility and feeding ability:
  • 15-year-old: immobile + tube fed → life expectancy ~13 additional years
  • 15-year-old: ambulatory + self-feeding → life expectancy ~55 additional years
• Death related to: aspiration pneumonia, UTI/sepsis, seizures, fractures
• Higher mortality factors: female sex, cognitive impairment, epilepsy, dyskinetic subtype
• CP is a lifelong condition - transition planning to adult services is essential
• Bradley & Daroff's Neurology, p. 2877

Recent Evidence (PubMed 2024-2025)

• A 2025 Lancet Review by Novak, Jackman & Finch-Edmondson provides updated comprehensive guidance on CP management
• A 2024 JAMA Pediatrics meta-analysis (Lewis et al.) highlights the clinical actionability of genetic findings in CP - supporting routine genetic testing, as up to 30% of CP cases may have identifiable genetic causes
• A 2024 pediatric clinical practice review (Patel et al., Curr Probl Pediatr Adolesc Health Care) provides updated clinical management guidelines

References

Textbooks

1. Daroff RB, Jankovic J, et al., eds. Bradley and Daroff's Neurology in Clinical Practice, 8th ed. Philadelphia: Elsevier; 2022. Chapter 111, pp. 2877-2884. [Definition, Epidemiology, Etiology, Classification, Diagnosis, Treatment]
2. Azar FM, Beaty JH, eds. Campbell's Operative Orthopaedics, 15th ed. Philadelphia: Elsevier; 2026. Chapters 35 and 40. [Orthopaedic Management, SEMLS, Scoliosis, Hip Surveillance]
3. Miller MD, Thompson SR, eds. Miller's Review of Orthopaedics, 9th ed. Philadelphia: Elsevier; 2024. Chapter on CP, pp. 5707-5809. [Classification, Surgical Procedures]
4. Norman Williams, et al., eds. Bailey and Love's Short Practice of Surgery, 28th ed. Boca Raton: CRC Press; 2022. Chapter 44, pp. 9260-9329. [Classification Table, Surgical Procedures Table - Neuromuscular Conditions]
5. Hughes HK, Kahl LK, eds. The Harriet Lane Handbook, 23rd ed. (Johns Hopkins Hospital). Philadelphia: Elsevier; 2021. [Pediatric pharmacology reference]

Journals

1. Novak I, Jackman M, Finch-Edmondson M. Cerebral palsy. Lancet. 2025;406(10):doi:10.1016/S0140-6736(25). [PMID: 40550230]
2. Lewis SA, Chopra M, Cohen JS. Clinical Actionability of Genetic Findings in Cerebral Palsy: A Systematic Review and Meta-Analysis. JAMA Pediatr. 2025 Feb 1. [PMID: 39621323]
3. Patel DR, Bovid KM, Rausch R. Cerebral palsy in children: A clinical practice review. Curr Probl Pediatr Adolesc Health Care. 2024 Nov. [PMID: 39168782]
4. Rosenbaum P, et al. A report: The definition and classification of cerebral palsy. Dev Med Child Neurol. 2007;49(Suppl 109):8-14.
5. Palisano RJ, et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39:214-223.

What Was Good (Why 8.5)

• Structured headings and tables
• GMFCS included
• Associated conditions covered
• Recent PubMed references added
• Clinical images included

What I'll Improve Going Forward

1. Age-Specific Developmental Milestones

2. Pediatric-First Textbooks as Primary Sources

3. Pediatric Drug Dosing Tables

4. Screening Tools Used in Pediatric Practice

• General Movements Assessment (GMA) - for infants <5 months (fidgety movements)
• Hammersmith Infant Neurological Examination (HINE)
• DAYC-2, Bayley-III - developmental assessment
• CPQOL-Child - quality of life in CP

5. Early Diagnosis Section (0-2 Years)

6. IAP / WHO / AAP Guideline References

7. Vaccination and Preventive Care

• Annual influenza vaccine (aspiration risk)
• Pneumococcal vaccine
• Vitamin D / calcium supplementation
• Bone health monitoring

8. Comorbidity Management with Pediatric Dosing

9. Caregiver and Family Counseling Section

10. Flowchart / Decision Algorithm

Gaps Identified and My Fixes

1. Diagnostic Criteria - Too Absolute

• Problem: Said CP requires "ALL five criteria" - too rigid
• Fix: Will present criteria as clinical judgment-based, acknowledging that diagnosis is primarily clinical and criteria are guiding principles, not a rigid checklist

2. Epidemiological Figures - Need Qualification

• Problem: Stated congenital 85-90%, acquired 10-15% as hard facts
• Fix: Will add "approximately," "varies by cohort," and cite specific study populations

3. Genetic Testing Figure - Needs Context

• Problem: "Up to 30%" stated without cohort context
• Fix: Will qualify - "10-30% depending on cohort selection, definition, and testing methodology (chromosomal microarray vs. exome sequencing)"

4. Life Expectancy Data - Potentially Misleading

• Problem: Specific figures ("13 additional years," "55 additional years") without source/population context
• Fix: Will cite the specific Strauss et al. cohort, add that these are population-based estimates and individual variation is wide

5. Missing: CP Diagnostic Algorithm

• Fix: Will include a clear flowchart every time:

Developmental concern (motor delay/abnormal tone)
        ↓
Detailed history + neurological examination
        ↓
Recognize CP pattern? (tone, reflexes, posture, milestones)
        ↓
Brain MRI (etiology + pattern correlation)
        ↓
Assess associated impairments (cognition, seizures, vision, hearing, speech)
        ↓
Classify: GMFCS + MACS + CFCS
        ↓
Screen for mimics / genetic disorders if atypical
        ↓
Multidisciplinary management plan

6. Missing: MACS and CFCS

• Problem: Only GMFCS was included
• Fix: Will include all three classification systems together:

7. Missing: Early Diagnosis Tools (GMA + HINE)

• Fix: Will add a dedicated "Early Diagnosis in Infancy" section covering:
  • General Movements Assessment (GMA) - absence of fidgety movements at 9-20 weeks corrected age has ~98% sensitivity for CP
  • Hammersmith Infant Neurological Examination (HINE) - score <57 at 3 months predicts CP
  • MRI - best before 2 years; shows etiology
  • Combined GMA + HINE + MRI = early diagnosis possible by 3-5 months corrected age (EACD 2017 guidelines)

8. References - Standardization

• Fix: Will use Vancouver/ICMJE format consistently with DOI where possible, distinguishing textbook chapters from journal articles clearly

Summary Table of Improvements